13F Holdings
中文EN

TMDX TransMedics Group, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1756262 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY28.5%
TTM net income YoY57.4%
TTM EPS YoY48.0%
Revenue 3-yr CAGR56.0%
Net income 3-yr CAGR—

Margins

Gross margin58.6%
Operating margin11.9%
Net margin19.9%
FCF margin6.1%
EBITDA margin17.4%

Returns

ROE31.9%
ROA11.7%
ROIC (approx.)—
Asset turnover0.59x

Leverage & solvency

Liabilities / assets63.7%
Debt / equity0.00x
Current ratio4.53x
Interest coverage3.46x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio2.6%
Payout ratio—
Capex / revenue9.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$605.49M$441.54M$241.62M$93.46M$30.26M
Cost of revenue$242.69M$179.46M$87.53M$28.19M$9.10M
Gross profit$362.81M$262.08M$154.09M$65.27M$21.16M
R&D expense$69.06M$55.97M$36.05M$26.81M$22.30M
SG&A expense$185.17M$168.62M$119.55M$69.90M$38.28M
Operating income$108.58M$37.50M-$28.73M-$31.44M-$39.43M
Interest expense$13.78M$14.41M$10.79M$3.73M$3.87M
Pretax income$107.52M$35.78M-$26.67M-$36.16M-$44.18M
Income tax-$82.77M$316,000-$1.64M$66,000—
Net income$190.29M$35.46M-$25.03M-$36.23M-$44.22M
EBITDA$135.77M$57.25M-$20.55M-$27.96M-$37.61M
EPS (basic)5.601.07-0.77-1.23-1.60
EPS (diluted)4.871.01-0.77-1.23-1.60
Dividends declared per share0.000.000.000.000.00
Weighted avg. shares (diluted)40.54M35.22M32.52M29.56M27.62M
Balance sheet
Cash & equivalents$488.87M$337.15M$395.31M$201.68M$26.08M
Short-term investments————$66.87M
Receivables$84.28M$97.72M$63.58M$27.61M$5.93M
Inventory$48.88M$46.55M$44.23M$20.61M$14.86M
Current assets$637.78M$497.22M$510.65M$252.29M$118.70M
PP&E, net$327.66M$285.97M$173.94M$19.22M$9.84M
Goodwill$11.55M$11.55M$11.99M——
Intangibles$1.95M$2.15M$2.35M——
Total assets$1.07B$804.08M$706.05M$277.15M$134.89M
Current liabilities$89.31M$59.91M$54.93M$23.66M$23.24M
Short-term debt$10.00M————
Long-term debt———$58.70M$35.20M
Total debt———$58.70M$35.20M
Total liabilities$595.27M$575.47M$568.85M$89.77M$67.04M
Shareholders' equity$473.10M$228.60M$137.20M$187.38M$67.85M
Net debt———-$142.99M$9.12M
Shares outstanding34.27M33.62M32.67M32.14M27.79M
Cash flow statement
Operating cash flow$192.84M$48.80M-$13.03M-$45.82M-$28.86M
Capital expenditure$59.25M$129.74M$151.85M$11.91M$3.52M
Free cash flow$133.59M-$80.94M-$164.88M-$57.72M-$32.38M
Investing cash flow-$59.25M-$129.30M-$193.95M$54.51M$29.27M
Financing cash flow$16.86M$22.87M$400.42M$167.93M$1.39M
Depreciation & amortization$27.18M$19.76M$8.18M$3.48M$1.82M
Stock-based compensation$36.86M$33.22M$19.79M$10.32M$6.88M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.